Kupando Raises €10 Million to Advance Dual TLR Agonist KUP101 into Phase 1b Clinical Trial
核心洞察
Kupando (搜索), a German biotech company, secured an additional €10 million in Series A extension funding, bringing total Series A funding to €23 million to advance its lead immunotherapy candidate KUP101.
The company's lead asset KUP101 is a dual TLR4 (搜索) and TLR7 (搜索) agonist designed to activate innate immunity against cancer and drug-resistant infections through trained immunity mechanisms.
Funding will support a Phase 1b clinical study of KUP101 in patients with advanced solid tumors and accelerate preclinical programs targeting antimicrobial-resistant infections.
Kupando (搜索), a Germany-based biotech company developing therapies for cancer and infectious diseases, has raised an additional €10 million in Series A funding, bringing the total to approximately €23 million. The financing was co-led by Remiges Ventures (搜索) and LifeCare Partners (搜索), with participation from Brandenburg Kapital (搜索), High-Tech Gründerfonds (搜索), Ventura BioMed Investors (搜索), and new investor CARMA Fund (搜索).
The company plans to use the proceeds to advance the Phase 1b clinical study of its lead candidate, KUP101, in patients with advanced solid tumors, while also accelerating its preclinical pipeline targeting infectious diseases.
Dual TLR Agonist Platform Targets Innate Immunity
Kupando (搜索) is focused on leveraging innate immune stimulation and trained immunity through dual Toll-Like Receptor agonists. KUP101 is a dual TLR4 (搜索) and TLR7 (搜索) agonist, formulated as two small molecules co-encapsulated in a liposomal delivery system, designed to activate the immune system to fight cancer and infections.
The therapy has demonstrated a strong preclinical profile and represents a departure from most immunotherapy research in oncology, which has concentrated on the adaptive immune system. Instead, Kupando (搜索) has spent seven years building a therapeutic platform around the innate immune system, the body's older, faster-responding first line of defense that most pathogens and cancer cells have become adept at evading.
Toll-Like Receptors are pattern recognition proteins on immune cells that detect molecular signals from pathogens and trigger innate immune responses. Dual agonism of TLR4 (搜索) and TLR7 (搜索) simultaneously activates multiple immune pathways, inducing what immunologists call trained innate immunity: a form of epigenetic reprogramming that leaves innate immune cells in a heightened state of readiness long after the initial stimulus.
Tissue-Agnostic Approach Broadens Patient Population
The approach is tissue-agnostic, meaning it is not designed for a specific tumor type, which broadens its potential patient population. The company's broader pipeline includes programs targeting oncology indications such as skin cancer and solid tumors, as well as infectious disease applications including antimicrobial resistance and vaccine-related programs.
Addressing Antimicrobial Resistance
The antimicrobial resistance dimension represents a particularly significant opportunity. AMR, the accumulation of resistance to antibiotics and other antimicrobials across bacterial and fungal pathogens, is projected to become one of the leading causes of death globally by mid-century, yet the commercial incentives for developing new anti-infectives remain structurally weak.
An innate immunity stimulator that enhances the body's own defenses against drug-resistant organisms, rather than targeting the pathogen directly, represents a meaningfully different mechanism from conventional antibiotic approaches. The infectious diseases program is sponsored by Germany's Federal Ministry of Research, Technology and Space, according to the company.
Leadership and Scientific Foundation
Kupando (搜索) is led by CEO and Founder Johanna Holldack, a physician and serial biotech executive whose earlier career took her through CEO roles at MediGene AG, Telormedix SA, and Borean Pharma, and included a stint as a research associate at Harvard Medical School. The founding concept grew from an observation she made during a trip to Kenya: that animals relying solely on innate immunity, with no adaptive immune system to fall back on, are nonetheless capable of remarkable resilience against pathogens.
The scientific groundwork for KUP101 was laid at the laboratory of Prof. Dennis Carson at the University of California San Diego, whose research on TLR4 (搜索)/7 agonists has been central to the field. The company also appointed Jörn Aldag, a veteran biotech executive who previously guided uniQure to the first Western gene therapy regulatory approval and transformed Evotec through dual-listings on Frankfurt and NASDAQ, as chair of its board in February 2026.
Clinical Transition Milestone
The initial €13 million Series A closed in September 2022, with the same lead and co-lead investors. The additional €10 million signals that preclinical work is now sufficiently advanced to warrant the clinical investment. For a company that has spent the better part of a decade in preclinical development, the transition to Phase 1b marks the point at which the science must prove itself in patients.
"This additional funding is a testament to the potential of our innovative dual TLR agonist platform and will be instrumental in advancing KUP101 into clinical studies for solid tumors and accelerating our crucial work in infectious diseases," said Holldack. "Our mission is to leverage the natural resilience of the innate immune system to deliver truly transformative therapies for patients in critical need."
Martin Raditsch, Managing Partner of Carma Fund (搜索), noted that the round "underscores the confidence we, as investors, have in Kupando (搜索)'s science, team, and potential to deliver impactful solutions for unmet medical needs," describing the close as notable given the current challenging financial climate.